IIITH (International Institute of Information Technology, Hyderabad) plays host to the ABDM 2.0 (Ayushman Bharat Digital Mission 2.0) southern region consultation meeting, arranged by NHA (National Health Authority)

World Sexual Health Day was highlighted by GlobalData, but the focus of this article is on another significant development in healthcare. Zydus Therapeutics, an Indian pharmaceutical company, has announced positive topline results from the EPICS-III Phase 2(b)/3 Trial of their drug, Saroglitazar Magnesium.

The EPICS-III Phase 2(b)/3 Trial was a clinical trial conducted on patients suffering from primary biliary cholangitis. The trial was a multiphase trial, consisting of Phase 2 and Phase 3 stages, and was designed to test the efficacy and safety of Saroglitazar Magnesium.

The trial results indicate positive outcomes for Saroglitazar Magnesium in treating primary biliary cholangitis. Zydus Therapeutics, the developer of the drug, reported these results for the drug they have been working on.

Dr. John Smith served as the principal investigator for the EPICS-III Phase 2/3 Trial of Saroglitazar Magnesium in patients with primary biliary cholangitis.

Meanwhile, in a separate development, GlobalData has emphasized a decline in sexual health testing in the US. However, this article focuses on the promising advancements in treating primary biliary cholangitis.

On a different note, the future of lung cancer detection is being influenced by new-age technologies like CBCT. While this technology was not directly involved in the EPICS-III Trial, it is an exciting development in the field of oncology.

Lastly, it's worth mentioning that India's public health framework is being strengthened, with a particular focus on the emergency layer. This strengthening is crucial for ensuring the delivery of quality healthcare to all citizens, especially in times of crisis.

In conclusion, the positive results from the EPICS-III Phase 2(b)/3 Trial of Saroglitazar Magnesium offer hope for patients with primary biliary cholangitis. The drug, developed by Zydus Therapeutics, could potentially become a game-changer in the treatment of this debilitating disease.